Clinical Experience With Nintedanib For Idiopathic Pulmonary Fibrosis In 3 Uk Tertiary Interstitial Lung Disease Centres

被引：0
|
作者：
Toellner, H. [1 ]
Beswick, W. [2 ]
Crooks, M. [2 ]
Donaldson, C. [3 ]
Forrest, I. [3 ]
Hart, S. [2 ]
Leonard, C.
Major, M. [2 ]
Simpson, A. [3 ]
Chaudhuri, N. [4 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England
[3] Newcastle Upon Tyne Hosp NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Hosp South Manchester, Wythenshawe, Scotland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5384
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Appropriateness Of Prescribing Nintedanib For Idiopathic Pulmonary Fibrosis - An Institutional Experience
    Yau, S.
    Raheem, S.
    Rueda, A.
    Pandit, L.
    Bujarski, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [22] Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
    Amati, Francesco
    Stainer, Anna
    Polelli, Veronica
    Mantero, Marco
    Gramegna, Andrea
    Blasi, Francesco
    Aliberti, Stefano
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [23] Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
    Kolb, Martin
    Richeldi, Luca
    Behr, Juergen
    Maher, Toby M.
    Tang, Wenbo
    Stowasser, Susanne
    Hallmann, Christoph
    du Bois, Roland M.
    THORAX, 2017, 72 (04) : 340 - 346
  • [24] Clinical Features of Acute Exacerbation of Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis
    Miyashita, K.
    Kono, M.
    Saito, G.
    Koyanagi, Y.
    Tsutsumi, A.
    Kobayashi, T.
    Miki, Y.
    Hashimoto, D.
    Nakamura, Y.
    Suda, T.
    Nakamura, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [25] A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
    Rinciog, C.
    Watkins, M.
    Chang, S.
    Maher, T. M.
    LeReun, C.
    Esser, D.
    Diamantopoulos, A.
    PHARMACOECONOMICS, 2017, 35 (04) : 479 - 491
  • [26] A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
    C. Rinciog
    M. Watkins
    S. Chang
    T. M. Maher
    C. LeReun
    D. Esser
    A. Diamantopoulos
    PharmacoEconomics, 2017, 35 : 479 - 491
  • [27] Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre
    Sabina, Guler A.
    Pascal, Zumstein
    Sabina, Berezowska
    Alexander, Poellinger
    Thomas, Geiser
    Manuela, Funke-Chambour
    SWISS MEDICAL WEEKLY, 2018, 148
  • [28] Diagnosis and treatment of interstitial lung disease: focusing on idiopathic pulmonary fibrosis
    Kang, Hye-Rin
    Choi, Sun Mi
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2020, 63 (03): : 159 - 168
  • [29] Australasian interstitial lung disease registry idiopathic pulmonary fibrosis update
    Chee, M.
    Corte, T.
    Khor, Y.
    Jackson, D.
    Glaspole, I
    Wilsher, M.
    Wrobel, J.
    Gallagher, H.
    Chambers, D.
    Goh, N.
    DeBoer, S.
    Edwards, A.
    Royals, K.
    Reynolds, P.
    Thien, F.
    RESPIROLOGY, 2023, 28 : 184 - 185
  • [30] Nintedanib prevented fibrosis progressin and lung cancer growth in idiopathic pulmonary fibrosis
    Fukunaga, Kentaro
    Yokoe, Shinya
    Kawashima, Satoru
    Uchida, Yasuki
    Nakagawa, Hiroaki
    Nakano, Yasutaka
    RESPIROLOGY CASE REPORTS, 2018, 6 (08):
12345